Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 8. Graphical representation of a series of test compounds ranked by rates of time-dependent inhibition (kobs). The line includes new chemical entities (drug candidates), and marketed drugs are indicated with filled triangles (▲) (Zimmerlin et al., 2011). Reprinted from Drug Metab. Dispos., Vol. 39, Zimmerlin, A., Trunzer, M. and Faller, B., CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs, pages 1039-1046 (Zimmerlin et al., 2011), Copyright (2011), with permission from American Society for Pharmacology and Experimental Therapeutics.
Biomolecules & Therapeutics 2022;30:1~18
© Biomolecules & Therapeutics